Atropos Health Announces Strategic Financing to Fund International Expansion and Support Key Channel Partnerships

Leader in Unlocking Real-World Data for Healthcare Moves to Address the Global Evidence Gap in Markets Plagued by Tight Data Restrictions and a Lack of Clinical Trial Diversity Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced that it has completed a strategic financing from Presidio Ventures, the venture arm of Sumitomo Corporation Venture Group, Samsung Next, a venture arm of Samsung Electronics, Gaingels, Audere Capital, and others. The funding enables Atropos Health to accelerate commercial and development opportunities outside the U.S., using its proprietary technology and approach. The initial focus centers on key customers in Japan and Brazil. “While the lack of representation in clinical trials creates an evidence gap for up to 70 percent of U.S patients, this effect is even more pronounced internationally. Lack of representation and relevant evidence on local populations leads to poorly informed treatment decisions and worse outcomes for patients around the world,” said Dr. Brigham Hyde, Co-Founder and CEO at Atropos Health. “The support from our new strategic investors, Presidio and Samsung Next, and international healthcare partners underscores the value we deliver on a global scale– to unlock real-world data for evidence-based medicine.” Atropos Health offers the world’s first award-winning platform for faster data evaluation, evidence generation, and Generative AI in...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Analitica Atropos Health Audere Capital Dr. Brigham Hyde DVX Gaingels Health IT Funding Health IT Fundings Health IT Investment Presidio Ventures Project 360 LTD Rameen Rana Samsung Electronics Source Type: blogs